Drug Approval | March 09, 2024
USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility
The company will provide comprehensive response to USFDA for the observations
The company will provide comprehensive response to USFDA for the observations
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Acquisition of exclusive commercialization rights for European markets
Connecting new production and consumption areas of chilled food by low-carbon transportation services
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The product will be launched in March 2024
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla completes transfer of Generics Business Undertaking
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
